Portal de Periódicos da CAPES

Artigo Acesso aberto Produção Nacional Revisado por pares

BIBTEX RIS

Cannabinoids in Neurology - Position paper from Scientific Departments from Brazilian Academy of Neurology

2021; Thieme Medical Publishers (Germany); Volume: 79; Issue: 4 Linguagem: Inglês

10.1590/0004-282x-anp-2020-0432

1678-4227

Sônia Maria Dozzi Brucki, Tarso Adoni, Carlos Maurício Oliveira de Almeida, Daniel Ciampi de Andrade, Renato Anghinah, Luciana Mendonça Barbosa, Rodrigo Bazán, Alzira Alves de Siqueira Carvalho, W. de Carvalho, Paulo Pereira Christo, Marcus Vinícius Della Coletta, Adriana Bastos Conforto, Ylmar Corrêa Neto, Eliasz Engelhardt, Marcondes C. França, Clélia Maria Ribeiro Franco, Felipe von Glehn, Hélio Rodrigues Gomes, Caroline de Barros Gomes, Alexandre Ottoni Kaup, Fernando Kowacs, Aline Mizuta Kozoroski Kanashiro, Victor Gonçalves LOPES, Débora Palma Maia, Maria Luíza Giraldes de Manreza, Alberto Rolim Muro MARTINEZ, Sandra Cristina Gonçalves Martinez, Saulo Nardy Nader, Luciana de Oliveira Neves, Ivan Hideyo Okamoto, Rogério Adas Ayres de Oliveira, Fabiano de Melo, Cristiana Borges Pereira, Roberta Arb Saba, Letícia Pereira de Brito Sampaio, Lucas Porcello Schilling, Marcus Tulius T. Silva, Emanuelle Roberta da Silva Aquino, Jerusa Smid, Cristiane Soares, Manoel Alves Sobreira-Neto, Nise Alessandra de Carvalho Sousa, Leonardo Cruz de Souza, Hélio Afonso Ghizoni Teive, Vera C. Terra, Matheus VALE, Vítor Mendes, Edmar Zanoteli, Gilmar Fernandes do Prado,

Neurological and metabolic disorders

Cannabinoids comprehend endocannabinoids, phytocannabinoids, and synthetic cannabinoids, with actions both in the central and peripherical nervous systems. A considerable amount of publications have been made in recent years, although cannabis has been known for over a thousand years. Scientific Departments from the Brazilian Academy of Neurology described evidence for medical use in their areas. Literature is constantly changing, and possible new evidence can emerge in the next days or months. Prescription of these substances must be discussed with patients and their families, with knowledge about adverse events and their efficacy.